$0.00
96.67% day before yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US13089P1012
Symbol
CALA
Sector
Industry

Calithera Biosciences, Inc. Stock price

$0.00
+0.00 900.00% 1M
-0.02 95.00% 6M
-0.03 96.67% YTD
-0.05 98.00% 1Y
-48.00 100.00% 3Y
-65.00 100.00% 5Y
-188.20 100.00% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.00 0.00%
ISIN
US13089P1012
Symbol
CALA
Sector
Industry

Key metrics

Market capitalization $0.00
EBIT (operating result TTM) EBIT $-42.07m
Short interest 8.92%

Is Calithera Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Calithera Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Calithera Biosciences, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Calithera Biosciences, Inc.:

Buy
100%

Financial data from Calithera Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '22
+/-
%
- -
-
100%
- Direct Costs 1.39 1.39
3% 3%
-
-1.39 -1.39
117% 117%
-
- Selling and Administrative Expenses 11 11
39% 39%
-
- Research and Development Expense 29 29
72% 72%
-
-41 -41
64% 64%
-
- Depreciation and Amortization 1.39 1.39
3% 3%
-
EBIT (Operating Income) EBIT -42 -42
63% 63%
-
Net Profit -21 -21
82% 82%
-

In millions USD.

Don't miss a Thing! We will send you all news about Calithera Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Calithera Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
more than one year ago
Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023 Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023
Neutral
Seeking Alpha
almost 2 years ago
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies Swayampakula Ramakanth - H.C. Wainwright & Co. Matthew Cowper - SVB Securities Aydin Huseynov ...
Neutral
GlobeNewsWire
almost 2 years ago
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. E...
More Calithera Biosciences, Inc. News

Company Profile

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Susan Molineaux
Founded 2010
Website www.calithera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today